Physician profile
Michael H Park
NPI 1568404481
$3,185.44
in general payments reported to CMS, 2019-2025
44 companies · $1,213 in 2025
The $1,213 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.06 · 2021: $29.17 · 2022: $217 · 2023: $884 · 2024: $830 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Honoraria: $200 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.80 |
| Honoraria | $200.00 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $326.42 | 2022-2025 | |
| Daiichi Sankyo INC. | $254.27 | 2023-2025 | Enhertu, Datroway |
| Amgen INC. | $250.92 | 2022-2025 | Imdelltra (Amg757), Nplate, Xgeva |
| Pfizer INC. | $229.74 | 2023-2025 | |
| Abbvie INC. | $205.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $158.64 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $137.11 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $114.77 | 2021-2025 | Trodelvy |
| Celgene Corporation | $99.57 | 2024-2025 | Reblozyl |
| Array Biopharma INC | $81.96 | 2023-2025 | Mektovi, Xalkori, Lorbrena |
| Blueprint Medicines Corporation | $71.01 | 2022-2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $70.37 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Puma Biotechnology, INC. | $68.59 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.16 | 2023-2025 | Opdivo |
| Kite Pharma, INC. | $60.41 | 2024 | Yescarta |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.